~" The authors studied the effect of intracarotid administration of histamine on the regional cerebral blood flow (rCBF) in transplanted rat C6 glioma by the hydrogen clearance method. Histamine infusion at doses of 1 and 10 ug/kg/min produced an increase of rCBF in the tumor (24.6% _+ 16.4%, p < 0.002, and 37.6% _+ 18.2%, p < 0.0001, respectively) and also in brain surrounding the tumor (26.8% + 16.2%, p < 0.002, and 34.9% _+ 9.2%, p < 0.0001, respectively) without any significant changes in the ipsilateral hemisphere. Intravenous administration of pyrilamine (H, antagonist) and cimetidine (H2 antagonist) reduced blood flow responses to histamine; cimetidine was a more effective blocking agent than pyrilamine. Intracarotid infusion of histamine (1 and 10 ug/kg/min) with intravenous injection of Evans blue dye disclosed the selective extravasation of dye in the tumor and the brain surrounding the tumor.
V
ARIOUS neurotransmitters, such as noradrenaline, 5-hydroxytryptamine, acetylcholine, and neuropeptide Y, have been reported to regulate regional cerebral blood circulation and permeabilityJ ~ Their action on in vitro cerebral vessels, however, have differed according to drug concentration, the diameter of vessels, vascular tonus, and the condition of the endothelium. On the other hand, blood vessels in brain tumors are structurally j L28,2~ and biochemically 2"3"26"27"33 different from normal cerebral vessels. The regulatory action of neurotransmitters to brain tumor vessels has been studied only with noradrenaline. Panther, et al., 33 reported a reduction of intratumoral blood flow following the intravenous infusion of noradrenaline in a canine brain-tumor model.
Histamine is regarded as one of the most potent natural vasoactive substances in the peripheral organs, 31 ' 35 and has been detected in cerebral perivascular mast cells 82~ and the cerebrovascular smooth muscle. J3 Thus, this amine has been proposed as a vasoactive neurotransmitter j4'38 because of the histaminergic innervation of the cerebral microvasculature. 4~ Histaminergic vasodilatory effects on the normal pial vessels and arterioles have been shown in vitro in isolated arteries 4"7'1~ and in vivo with perivascular microapplication 5'9'~7'45 and cortical superfusion. 23 '37 The vasodilatory effect of histamine is mediated by HI and '45 There are, however, few studies of histamine in terms of the regional cerebral blood flow (rCBF) in the normal cerebral vessels. A histamine-induced increase of the rCBF in vivo has been obtained only following a hyperosmolar disruption of the blood-brain barrier, iv and these changes have not yet been studied in brain tumors.
H2 receptors. 4"L9-jlAS-17~39"43
In this study, we analyzed in rats the effect of intracarotid administration of histamine on the rCBF in brain tumors as well as in brain tissue surrounding the tumor (BST) in the ipsilateral hemisphere. In addition, the mechanism of histamine-induced selective rCBF increase in the tumor is discussed with the results of a receptor antagonist study and an Evans blue dye (EB) extravasation test.
Materials and Methods
Forty-five male Wistar rats. each weighing 200 to 260 gm, were used for the experiment. Four rats underwent sham operations and the remainder received tumor cell implantation.
Tumor Inoculation
First, C6 glioma cells were subcultured in Ham's F-10 medium containing 10% fetal bovine serum. 22 Tumor cells (5 x 105 in a 5-ul solution of Dulbecco's modified Eagle's medium with methyl cellulose) were stereotactically implanted into the fight cerebral hemisphere of rats while anesthetized with intraperitoneal pentobarbital sodium (Nembutal, 50 mg/kg). The sham operation was performed with an injection of the same solution without tumor cells.
Animal Preparation
The rats were studied under intraperitoneal pentobarbital anesthesia (50 mg/kg) 11 to 21 days after tumor inoculation. A tracheotomy was performed with catheter placement in the femoral arteries, veins, and internal carotid artery, as previously described in detail5 Each animal was mounted onto a stereotactic apparatus, immobilized with intravenous pancuronium (0.6 mg/kg), and mechanically ventilated with room air. During the experiment, anesthesia was maintained with 0.2% to 0.5% halothane, and the arterial blood pressure was monitored. End-tidal CO2 and rectal temperature were also monitored continuously and adjusted regularly throughout each experiment. 2 After the arterial blood pressure stabilized, arterial blood samples were taken for blood gas analysis.
Blood Flow Measurement
Two burr holes were made in the parietal bone; one was placed 4 mm lateral and 2 mm anterior to the bregma in both the sham-operated rats and the tumorimplanted rats, and the other was placed 5 mm posterior to it in the sham-operated rats and 3 to 8 mm posterior in the tumor-implanted rats. Two Teflon-coated platinum electrodes, 0.2 mm in diameter, were inserted through the burr holes to measure the rCBF. The referred electrodes were then inserted under the skin. The rCBF was measured by the hydrogen clearance method with a digital tissue blood flowmeter,* as described previously. 2 
Experimental Protocol
In the control experiments, all animals were given 0.9% saline through the internal carotid artery by a constant infusion at a rate of 1.5 ml/hr. Histamine was dissolved in 0.9% saline and administered into the carotid artery at the same infusion rate as saline.
Histamine infusion was begun 10 minutes before blood flow measurements, at doses of 1, 10, and 20 ug/ kg/min in the sham-operated rats, and 1 and 10 ug/kg/ * Digital UH-meter, Model MHG-DI, manufactured by Unique Medical Co., Tokyo, Japan. rain in the tumor-implanted rats. Histamine receptor blocking experiments were conducted by the method of Gross, et al. ~6 The histamine H~ receptor antagonist pyrilamine and the histamine H2 receptor antagonist cimetidine were administered intravenously (5 mg/kg) 10 minutes before histamine infusion. After the blood pressure stabilized, rCBF was measured during administration of histamine.
To assess blood-brain barrier permeability, histamine was administered into the carotid artery at a dose of 1 or 10 ug/kg/min for 10 minutes in five rats for each dose. A 2-ml/kg bolus of 2% EB was given intravenously immediately after histamine infusion. Saline was infused instead of histamine in five control rats. The rats were decapitated 20 minutes after the EB injection.
Histological Studies
After completion of the experiments, the rats were killed with an overdose of pentobarbital sodium, and the brains were removed and fixed with 10% formalin for blood flow measurement. The rats receiving EB injection were perfused with Ringer's solution through the aorta until the fluid from the caval vein became clear. Extravasation of EB was visually investigated in the removed brain and graded as none, slight, or moderate. The specimens were then embedded in paraffin or frozen, then sectioned, stained with hematoxylin and eosin, and examined microscopically. The electrode tracks were carefully examined, and the brains with either massive hemorrhage or necrosis were excluded from analysis. The ipsilateral basal ganglion 5 mm from the needle track in the sham-operated rats was defined as the normal control. Portions of the brain within 3 mm of the tumor edge were defined as the BST, while portions of the brain more than 3 mm from the tumor edge were defined as the ipsilateral hemisphere without tumor cells after histological confirmation.
Statistical Analysis
The data were expressed as mean + standard deviation. Statistical analysis was performed with the paired and unpaired Student's t-test, and analysis of variance. A probability of 0.05 or less was considered significant.
Results

Physiological Status
The animals were separated into two groups: the sham-operated group and the tumor-implanted group. Before drug administration, arterial blood gas (pH, PaCO2, and PaO2) measurements and the mean arterial pressure were obtained (Table 1 ). There were no significant differences in these physiological parameters between the two groups.
Regional Cerebral Blood Flow
Because the intracarotid infusion of histamine at a dose of 20 ug/kg/min significantly decreased the systemic blood pressure in the sham-operated rats (116.3 + 4.8 to 95.0 _+ 4.1 ml/min/100 gm, p < 0.004), further experiments were performed with histamine at doses of 1 and 10 ug/kg/min. Values were compared for both groups using an unpaired t-test, and the differences were not significant.
Sham-Operated Rats. The baseline rCBF in the sham-operated lesion was significantly higher than that of the normal control (59.2 _+ 13.9 and 39.9 _+ 6.1 ml/ min/100 gm, respectively, p < 0.05). Although the experiments were performed 14 days (on the average) after the sham operation, some tissue injury due to needle insertion might have been responsible for such a difference. The intracarotid infusion of histamine, however, did not significantly change rCBF either in the sham-operated lesion or in the normal control (Table 2) .
Tumor-Implanled Rats. Before histamine infusion, the mean rCBF for both infusion rates calculated together was significantly higher in the tumor than in the ipsilateral hemisphere (63.4 _+ 14.5 and 35.4 _+ 9.6 ml/ min/100 gm, respectively, p < 0.0002). The rCBF in the BST was not significantly different from that in the ipsilateral hemisphere (37.3 _+ 9.0 and 35.4 _+ 9.6, respectively, p = 0.61). Intracarotid infusion of hista-T. Nomura, etal. mine significantly increased the rCBF both in the tumor and the BST (p < 0.002) ( Table 2 ). In contrast, the rCBF in the ipsilateral hemisphere did not increase during intracarotid injection of histamine, even at a dose of 10 ug/kg/min.
The percent increases in the rCBF produced by 1 and lO ug/kg/min of histamine were 24.6% _+ 16.4% and 37.6% _+ 18.2% in the tumor, respectively; in the BST, levels of 26.8% + 16.2% and 34.9% + 9.2% above preinfusion values were observed, respectively. These percent increases of the rCBF in the tumor and the BST were significantly higher than that in the normal or sham-operated rats (p < 0.02) ( Table 2 ).
The specific histamine receptor antagonists, pyrilamine (HI) and cimetidine (H2), did not affect either the rCBF or the mean arterial pressure at a dose of 5 mg/kg intravenously (data not shown). When the rats were pretreated with histamine blockers 10 minutes before histamine infusion, the percent increases of the rCBF were 14.3% _+ 1.8% in the tumor and 23.1% _+ 5.1% in the BST with pyrilamine infusion, and 10.9% + 4.1% in the tumor and 9.2% + 2.7% in the BST with cimetidine infusion (Fig. 1) . The histamine-induced selective increase of the rCBF in the tumor and the BST was significantly reduced with preadministration of the H~ blocker by 63% and 34% (p < 0.05), and with the H2 blocker by 71% and 74% (p < 0.01), respectively. The H2 antagonist was more potent in reducing the histamine-induced rCBF increase both in the tumor and in the BST when compared to the H~ antagonist, although there was no significant difference between them.
Blood-Brain Barrier Permeability
All five control rats tested for blood-brain barrier permeability showed no definite extravasation of EB macroscopically after the intracarotid saline infusion (Fig. 2 ). Histamine at a dose of I Fzg/kg/min in five rats produced a slight homogeneous EB extravasation in the tumor except for one which showed no definite extravasation of EB and no significant extravasation in the extratumoral brain. In the five rats receiving histamine at a dose of 10 ug/kg/min, a moderate homogeneous extravasation of EB both in the tumor and in the BST was observed in all five rats without significant extravasation in the extratumoral ipsilateral brain.
Discussion
There were three principal findings in this study. 1) The intracarotid infusion of histamine increased rCBF both in the tumor and in the BST without affecting rCBF in the extratumoral ipsilateral cerebrum.
2) The histamine-induced selective increase of the rCBF in the tumor and the BST was blocked by intravenous administration of histamine HI and H2 receptor antagonists.
3) Intracarotid histamine infusion obtained a selective increase in blood-tumor barrier permeability.
Histamine has been reported to increase blood flow in the cerebral arterial trunks in dogs; for example, basilar arterial blood flow was increased by 145% (25 ug/kg, intravenous injection) l and carotid arterial blood flow by 400% (6.4 #g/kg, intra-arterial injection) 3~' 42 by electromagnetic flow measurement. On the other hand, rCBF in the brain parenchyma, measured by the '33Xe clearance method, was not affected by intracarotid administration of histamine in a range of 0.1 to 60 ug/ kg/min. 12t6 Our findings, which showed no significant changes of the rCBF in the normal brain, also support this phenomenon. There was an interesting report by Gross, et al., ~6 showing that intracarotid administration of histamine (6 to 60 ug/kg/min) increased the rCBF in the normal brain only after the osmotic opening of the blood-brain barrier in anesthetized rats by 27% to 50% using the ~33Xe clearance method of measurement and by 9% to 31% based on ~4C-iodoantipyrine autoradiography. In our study, intracarotid infusion of histamine (1 or 10 ug/kg/min) also increased the rCBF both in the tumor and in the BST by 25% or 38%, respectively, without affecting the rCBF in the extratumoral ipsilateral cerebrum. Considering that increased permeability was found in the tumor and/or the BST in the experimental brain tumors, 22"34"4~ these findings lead us to the following speculations. 1 ) In normal conditions, intraluminal histamine increases the blood flow in the cerebral main arterial trunk and does not affect the capillary blood flow (rCBF) because of the existence of the blood-brain barrier and autoregulation.
2) The osmotic disruption of the blood-brain barrier and/or increased permeability in the brain tumor might allow intraluminal histamine to extravasate into the luminal side at the level of the arterioles. 3) Thereafter, histamine binding to Hj and H2 receptors, which exist in the inner layers of vascular smooth muscle, produce their vasodilating effects selectively on capillaries in the affected lesion.
lntracarotid administration of histamine induced the selective increase of EB extravasation in the brain tumor and the BST in our study. Although there have been reports that the cortical superfusion (10 -9 to 10 -4 M) 3~ or intravascular administration (2 to 500 ttg/kg/ min)6.~8.~9 of histamine elicited extravasation of various tracers into the normal brain tissue, a selective increase of blood-tumor barrier permeability was obtained in our experimental protocol. Thus, the histamine-induced selective increase of the rCBF in the tumor and the BST might be enhanced by the increased permeability conducted by histamine itself.
The intratumoral blood flow shows an altered response to vasoactive agents, 2' 33"4~ induced hypertension, 24"25' 44 and CO2 changes 32"33 when compared to the blood flow in the normal brain tissue. In addition to the disruption of the blood-brain barrier in tumor tissue, the altered reactivity to vasoactive agents and the loss of autoregulation in the tumor may participate in these phenomena. Natori and colleagues 26'27 suggested that the altered reaction of tumor vessels to adenosine triphosphate and adenosine was due to the hyperreacfion of the receptor site in the endolhelium and smooth muscle. Although two classes of histamine receptor antagonist could not block the histamine-induced rCBF changes completely, our receptor blocking T. Nomura, et aL study might indicate that the rCBF in tumor vessels was also controlled by histamine and its receptor interaction.
Because of the different results among various animal species, it has not been clarified yet how these subclasses of histamine receptor interact with each other for brain circulation. Using isolated rabbit cerebral arteries, Sercombe, et al., 3~ showed that the HI receptor in smooth muscle mediates endothelium nondependent vasoconstriction and the H2 receptor in endothelium causes endothelium-dependent vasodilation. Recently, several reports have indicated that histamine-induced vasodilatation was mediated by both the H~ receptor on endothelium, which released endothelium-derived relaxing factor, and the H2 receptor in the smooth muscle. 443 In the present study, the H2 antagonist was a more potent inhibitor, indicating that the histamine-induced rCBF increase in the tumor was more dependent on the H2 receptor-mediated response. In addition, it is not clear whether the receptors, which account for histamine-induced rCBF changes, exist in the endothelium or in the smooth muscle, or whether tumor and the BST vessels might, in fact, possess different receptor characteristics in addition to morphological changes. 20, 28, 29 The selective action of histamine on the rCBF and permeability of brain-tumor vessels is thus considered to be an interesting phenomenon. Using the altered action of histamine as a means of selectively increasing permeability and rCBF in the tumor tissue may contribute to the selective delivery of the water-and lipidsoluble therapeutic agents. It is hoped that a clarification of the mechanisms of action of vasoactive agents on the blood vessels of the normal brain and tumor may assist in the management of malignant brain tumors either by chemotherapy or by other supplementary therapies.
